02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 44.48
−1.29%Margins
Gross margin
47.5%
EBITDA margin
40.1%
EBIT margin
32.4%
Net margin
21.2%
FCF margin
18.7%
10.4%
Return on equity
7.7%
Return on assets
15.1%
Return on invested capital
0.37x
Asset turnover
HKD 10.6B
Cash from operations
HKD 3.81
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026